Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 46: 896-900, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2000;46:896-900.)
© 2000 American Association for Clinical Chemistry, Inc.


Articles

Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger?

Eleftherios P. Diamandis1,a

1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
a Address for correspondence: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada. E-mail ediamandis{at}mtsinai.on.ca

Background: Prostate-specific antigen (PSA) is a valuable prostatic cancer biomarker that is now widely used for population screening, diagnosis, and monitoring of patients with prostate cancer. Despite the voluminous literature on this biomarker, relatively few reports have addressed the issue of its physiological function and its connection to the pathogenesis and progression of prostate and other cancers.

Approach: I here review literature dealing with PSA physiology and pathobiology and discuss reports that either suggest that PSA is a beneficial molecule with tumor suppressor activity or that PSA has deleterious effects in prostate, breast, and possibly other cancers.

Content: The present scientific literature on PSA physiology and pathobiology is confusing. A group of reports have suggested that PSA may act as a tumor suppressor, a negative regulator of cell growth, and an apoptotic molecule, whereas others suggest that PSA may, through its chymotrypsin-like activity, promote tumor progression and metastasis.

Summary: The physiological function of PSA is still not well understood. Because PSA is just one member of the human kallikrein gene family, it is possible that its biological functions are related to the activity of other related kallikreins. Only when the physiological functions of PSA and other kallikreins are elucidated will we be able to explain the currently apparently conflicting experimental data.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Cancer Res.Home page
V. D'Arcy, Z. K. Abdullaev, N. Pore, F. Docquier, V. Torrano, I. Chernukhin, M. Smart, D. Farrar, M. Metodiev, N. Fernandez, et al.
The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis.
Clin. Cancer Res., October 15, 2006; 12(20): 5978 - 5986.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. El-Bayoumy, J. P. Richie Jr., T. Boyiri, D. Komninou, B. Prokopczyk, N. Trushin, W. Kleinman, J. Cox, B. Pittman, and S. Colosimo
Influence of Selenium-enriched Yeast Supplementation on Biomarkers of Oxidative Damage and Hormone Status in Healthy Adult Males: A Clinical Pilot Study
Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1459 - 1465.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. P. Diamandis and G. M. Yousef
Human Tissue Kallikreins: A Family of New Cancer Biomarkers
Clin. Chem., August 1, 2002; 48(8): 1198 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. Niemela, J. Lovgren, M. Karp, H. Lilja, and K. Pettersson
Sensitive and Specific Enzymatic Assay for the Determination of Precursor Forms of Prostate-specific Antigen after an Activation Step
Clin. Chem., August 1, 2002; 48(8): 1257 - 1264.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
B. R. Grzeda, T. Le Bui, C. N. Warner, T. L. Pirucki, L. M. Dewey, M. Babich, and J. A. Maggiore
Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System
Clin. Chem., August 1, 2002; 48(8): 1272 - 1278.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. David, N. Mabjeesh, I. Azar, S. Biton, S. Engel, J. Bernstein, J. Romano, Y. Avidor, T. Waks, Z. Eshhar, et al.
Unusual Alternative Splicing within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-specific Proteins
J. Biol. Chem., May 10, 2002; 277(20): 18084 - 18090.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
F. J. Meng, A. Shan, L. Jin, and C. Y. F. Young
The Expression of a Variant Prostate-specific Antigen in Human Prostate
Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 305 - 309.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. M. Yousef and E. P. Diamandis
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease
Endocr. Rev., April 1, 2001; 22(2): 184 - 204.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.